Article
Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
PloS one - 26 Apr 2011
Balabanov Stefan, Gontarewicz Artur, Keller Gunhild, Raddrizzani Laura, Braig Melanie, Bosotti Roberta, Moll Jürgen, Jost Edgar, Barett Christine, Rohe Imke, Bokemeyer Carsten, Holyoake Tessa L, Brümmendorf Tim H
Abstract excerpt
The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM resistance and by a limited IM effect on hematopoietic stem cells. Danusertib (formerly PHA-739358) is a potent pan-aurora and ABL kinase inhibitor with activity against known BCR-ABL mutations, including T315I. Here, the individual contribution of both signaling pathways to the therapeutic effect of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.